Physician profile
Matthew A Asmar
NPI 1225573512
$13,315.43
in general payments reported to CMS, 2019-2025
30 companies · $4,858 in 2025
The $4,858 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.12 · 2022: $816 · 2023: $3,631 · 2024: $3,996 · 2025: $4,858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,985.97 |
| Education | $499.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,704.22 | 2022-2025 | |
| Dermavant Sciences, INC. | $1,048.00 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $943.59 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $894.52 | 2021-2025 | Sotyktu |
| Genzyme Corporation | $847.55 | 2023-2025 | |
| Galderma Laboratories, L.P. | $751.73 | 2023-2025 | Aklief, Nemluvio, Oracea |
| Leo Pharma INC. | $725.21 | 2023-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $702.93 | 2023-2025 | |
| Pfizer INC. | $646.76 | 2022-2025 | |
| Janssen Biotech, INC. | $638.02 | 2023-2025 | Tremfya, Simponi Aria, Simponi |
| Incyte Corporation | $607.37 | 2022-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $572.39 | 2022-2025 | Dupixent, Libtayo |
| Ucb, INC. | $465.29 | 2023-2025 | Bimzelx, Cimzia |
| Journey Medical Corporation | $247.08 | 2023-2025 | Emrosi |
| Lilly USA, LLC | $227.54 | 2023-2025 | Olumiant, Taltz, Ebglyss |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $208.51 | 2022-2025 | Otezla, Otezla |
| Organon LLC | $194.83 | 2024-2025 | Vtama, Hadlima |
| Botanix Sb INC | $191.91 | 2025 | Sofdra |
| Sanofi-Aventis U.S. LLC | $172.78 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $150.31 | 2022-2025 | Winlevi, Odomzo, Blu-U |
| Janssen Scientific Affairs, LLC | $124.36 | 2022 | |
| Almirall LLC | $54.86 | 2024-2025 | Klisyri, Seysara |
| Sanofi US Services INC. | $49.82 | 2024 | |
| Fidia Pharma USA INC. | $34.63 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $30.35 | 2023 | Jublia, Arazlo, Siliq |
| Mayne Pharma Commercial LLC | $18.40 | 2025 | |
| Mallinckrodt Hospital Products INC. | $17.98 | 2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.40 | 2023 | Spevigo |
| Lnhc, INC | $14.60 | 2025 | Zelsuvmi |
| Fresenius Kabi USA, LLC | $14.49 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Asmar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.